Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.74 |
| ▸ | CHUK | O15111 | 11/20 | 0.74 |
| ▸ | NEK1 | Q96PY6 | 7/20 | 0.66 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | LTK | P29376 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968231 | 0.85 | IKBKB (1.00) | IKBKBCHUKNEK1PIK3C3ROCK1 | |
| SCHEMBL4790144 | 0.80 | IKBKB (0.70) | IKBKBCHUKNEK1ROCK1DAPK3 | |
| SCHEMBL30009843 | 0.79 | IKBKB (0.70) | IKBKBCHUKNEK1PIK3C3ROCK1 | |
| SCHEMBL4968595 | 0.79 | IKBKB (1.00) | IKBKBCHUKNEK1PIK3C3ROCK1 | |
| SCHEMBL3252342 | 0.79 | IKBKB (0.52) | IKBKBCHUKROCK1JAK2MAP4K4 | |
| SCHEMBL100470 | 0.78 | AURKA (0.54) | IKBKBCHUKNEK1PIK3C3ROCK1 | |
| SCHEMBL858016 | 0.78 | CAMKK2 (0.60) | ROCK1DAPK3JAK2PRKD3MAP4K4 | |
| SCHEMBL30009525 | 0.78 | IKBKB (0.76) | IKBKBCHUKNEK1ROCK1DAPK3 | |
| SCHEMBL17220113 | 0.78 | AURKA (0.56) | IKBKBCHUKNEK1ROCK1JAK2 | |
| SCHEMBL24805260 | 0.77 | IKBKB (0.76) | IKBKBCHUKNEK1PIK3C3ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1962851-A2 | COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007076320-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | IKBKB 436/4885CHUK 212/4885NEK1 224/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | IKBKB 138/4885CHUK 31/4885NEK1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.